Business Wire

Global Processing Services Strengthens Executive Leadership Team with Trio of Appointments

7.10.2020 02:01:00 EEST | Business Wire | Press release

Share

Leading payments issuer processor, Global Processing Services (GPS), today announces its appointment of three C-level executives: Richard Hodgson as Chief Financial Officer, Shaun Puckrin as Chief Product Officer, and Jerome Gudgeon as Chief Technology Officer.

The new hires bolster the executive leadership team of GPS, the payments processing partner for some of the most well-known and successful fintechs on the market, including Revolut, Starling Bank and Curve, as the business drives its global expansion plans forward beyond Europe and APAC.

Richard Hodgson, Chief Financial Officer

As Chief Financial Officer, Richard Hodgson is responsible for scaling the GPS Finance function as it expands geographically, bringing more customers onto the GPS platform. A qualified accountant, Richard brings with him over 25 years of experience in Financial Services, Pharmaceuticals, and FMCG. Prior to joining GPS, Richard held senior positions at XE.com, HiFX, Travelex, and GlaxoSmithKline.

Shaun Puckrin, Chief Product Officer

Shaun Puckrin is responsible for setting the product strategy and roadmap at GPS in his role as Chief Product Officer, ensuring that these align with the company’s overall commercial strategy of providing the most reliable and feature-rich platform to GPS customers worldwide. With more than 20 years’ experience in payments, mobile and fintech, Shaun has a track record of developing award-winning B2B and B2C products whilst in senior product and technology positions at Worldpay, Nested, Monitise, and Symbian.

Jerome Gudgeon, Chief Technology Officer

In his capacity as Chief Technology Officer, Jerome Gudgeon spearheads the technology strategy and delivery for the business, which includes overall responsibility for the development and day-to-day technology operations of the GPS Apex platform. Having held senior technology and leadership positions at American Express, TD Bank, Fidelity and a Swiss Private Bank, Jerome brings more than 25 years’ experience in payments, investments and banking technology. Alongside this, he also founded two fintech start-ups in payments and investments.

Commenting on the new appointments, GPS Chief Executive Officer, Joanne Dewar, said: “We are thrilled to welcome Richard, Shaun and Jerome to the leadership team at GPS. Their collective wealth of experience stands to enrich the team and propel us forward into the next stage of our evolution, which will see GPS deploying our payments processing technology into new territories and advancing the next generation of fintechs, digital banks and e-wallet providers in the rapidly evolving ecosystem.

The payments and fintech space is growing by leaps and bounds around the world, so it is fundamental that GPS hires the right people and expertise in order to continue leading the charge in the payments processing space,” she concluded.

To find out more about GPS, visit: https://www.globalprocessing.com/

ENDS

About Global Processing Services (GPS)

Global Processing Services (GPS) is the trusted and proven go-to payments processing partner for today’s leading challenger brands, including Revolut, Starling Bank and Curve.

Founded in 2007, GPS’s highly flexible and configurable platform places the control firmly in the hands of global fintechs, digital banks and e-wallets, enabling them to deliver rich functionality to the cardholder.

GPS is certified by Mastercard and Visa to process and manage any credit, debit or prepaid card transaction globally, with offices in London, Newcastle, Singapore and Sydney. It is equipped to meet the stringent standards required by Tier 1 banks and has integrated with more than 40 issuing banks and operates programmes for 180+ clients in 60 countries, using over 150 currencies.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact
Becky Sales
becky@skyparlour.com / gps@skyparlour.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye